U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Biologics Post-Market Activities
  5. Lot Release
  6. Influenza Vaccine for the 2019-2020 Season
  1. Lot Release

Influenza Vaccine for the 2019-2020 Season

Cumulative 2019/2020 Season Lot Release Status (Updated 12/5/2019)

Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.

Manufacturer Total Number of Lots Released by FDA
Afluria Quadrivalent
Seqirus Pty. Ltd.
Seqirus, Inc.
Fluarix Quadrivalent
GlaxoSmithKline Biologicals
Flublok Quadrivalent
Protein Sciences Corporation
Flucelvax Quadrivalent
Seqirus, Inc.
FluLaval Quadrivalent
ID Biomedical Corporation of Quebec
FluMist Quadrivalent
MedImmune, LLC
Fluzone High Dose
Sanofi Pasteur, Inc.
Fluzone Quadrivalent
Sanofi Pasteur, Inc.

FDA's Vaccines and Related Biological Products Advisory Committee met in Silver Spring, Maryland, on March 6 and 22, 2019, to select the influenza viruses for the composition of the influenza vaccine for the 2019-2020 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2018-2019 vaccines, and the availability of candidate strains and reagents.

The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2019-2020 influenza season contain the following:

  • an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
  • an A/Kansas/14/2017 (H3N2)-like virus;
  • a B/Colorado/06/2017-like virus (B/Victoria lineage).

The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:

  • a B/Phuket/3073/2013-like virus (B/Yamagata lineage)
Back to Top